This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Innovator Norma I Rodriguez-Malave: Pioneering Research in Leukemia
Introduction
Norma I Rodriguez-Malave is a distinguished inventor based in Los Angeles, CA. She has made significant contributions to the field of cancer research, particularly in understanding the role of long intergenic non-coding RNAs (lincRNAs) in leukemia. Her innovative work has the potential to impact the diagnosis and treatment of this challenging disease.
Latest Patents
Rodriguez-Malave holds a patent titled "Methods and compositions involving lincRNA and leukemia." This patent reveals that lincRNA expression is associated with specific cytogenetic abnormalities and is linked to the disease pathogenesis of certain cancers. The research highlights the role of lincRNAs in gene regulation, particularly in B acute lymphoblastic leukemia (B-ALL). The patent provides methods and compositions related to B-ALL associated long intergenic RNAs (BALIRs), showcasing her groundbreaking findings in this area.
Career Highlights
Norma I Rodriguez-Malave is affiliated with the University of California, where she conducts her research. Her work has garnered attention for its innovative approach to understanding the genetic factors involved in leukemia. With a focus on lincRNAs, she is at the forefront of cancer research, contributing valuable insights that could lead to new therapeutic strategies.
Collaborations
Rodriguez-Malave collaborates with esteemed colleagues, including Dinesh S Rao and Ella Waters. These partnerships enhance her research efforts and contribute to the advancement of knowledge in the field of oncology.
Conclusion
Norma I Rodriguez-Malave is a pioneering inventor whose research on lincRNAs and leukemia is paving the way for new discoveries in cancer treatment. Her contributions to the scientific community are invaluable and hold promise for improving patient outcomes in leukemia.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
